LONDON — Roche on Wednesday reported positive early data from another of the obesity drug candidates that it picked up through an acquisition late last year, bolstering the case it could become a player in the competitive weight-loss medicine field.
The company said its once-daily pill, called CT-996, led to a placebo-adjusted average weight loss of 6.1% after four weeks in patients with obesity who did not have diabetes. The figures reported Wednesday came from an initial analysis of a Phase 1 trial, but with so much attention on the booming obesity-medicine arena, they lifted Roche shares by 5% in early trading.
Roche said it would advance CT-996 into a Phase 2 study.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect